Clinical correlates of lipoprotein (a) and apolipoprotein B levels in patients with dyslipidemia and cardiovascular disease - Top-Institutions - MDSpire

Clinical correlates of lipoprotein (a) and apolipoprotein B levels in patients with dyslipidemia and cardiovascular disease

  • By

  • Luana Alexandrescu

  • Daria Maria Alexandrescu

  • Ionut Tiberiu Tofolean

  • Doina Ecaterina Tofolean

  • Steliana Pindichi

  • Eugen Dumitru

  • Bogdan Campineanu

  • Cristina Aftenie

  • Andreea Nelson Twakor

  • Alexandra Herlo

  • Elena Rusu

  • Diana Raluca Baicu

  • Madalina Ilie

  • Filip-Vasile Berariu

  • Laura Maria Condur

  • July 9, 2026

  • 0 min

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    UK Biobank
    UK Biobank

    Cambridge, UK

    Key Differentiators

    • Cardiology
    • Epidemiology

  • #2

    Medsim Center
    Medsim Center

    Unknown, Unknown

    Key Differentiators

    • Cardiology

  • #3

    Copenhagen General Population Study
    Copenhagen General Population Study

    Copenhagen, Denmark

    Key Differentiators

    • Cardiology
    • Epidemiology

Original Source(s)

Clinical correlates of lipoprotein (a) and apolipoprotein B levels in patients with dyslipidemia and cardiovascular disease

  • by Luana Alexandrescu, Daria Maria Alexandrescu, Ionut Tiberiu Tofolean, Doina Ecaterina Tofolean, Steliana Pindichi, Eugen Dumitru, Bogdan Campineanu, Cristina Aftenie, Andreea Nelson Twakor, Alexandra Herlo, Elena Rusu, Diana Raluca Baicu, Madalina Ilie, Filip-Vasile Berariu, Laura Maria Condur

  • July 9, 2026

Related Content

AI Tool Finds More Long COVID Cases Than Codes

Nearly 90% of patients who met algorithmic criteria for postacute sequelae of SARS-CoV-2 infection had at least 1 chronic or potentially chronic condition requiring ongoing clinical management.

ACP Suggests First-Line Obesity Drugs

Semaglutide and tirzepatide had the greatest net benefit among evaluated treatments, the committee concluded.

Effectiveness of low-dose SGLT2 inhibitors in diabetic patients with heart failure: a nationwide cohort study